新辅助化疗联合曲妥珠单抗对HER-2过表达乳腺癌的疗效观察

目的:观察新辅助化疗联合曲妥珠单抗对HER-2过表达乳腺癌的临床疗效。方法:39例HER-2过表达的乳腺癌患者,均采用多西他赛及卡铂新辅助化疗联合曲妥珠单抗治疗,6个周期后观察疗效并对乳腺癌组织中雌激素受体(ER)表达状态与病理完全缓解(pCR)率之间行单因素分析。结果:39例患者总有效率(OR)为94.9%(37/39);其中临床完全缓解(cCR)26例(66.7%),部分缓解(PR)11例(28.2%),疾病稳定(SD)2例(5.1%),无疾病进展(PD)病例。病理完全缓解(pCR)27例(69.2%)。单因素分析显示,ER阴性组的pCR率为82.4%,ER阳性组为59.1%。结论:在HER-2过表达乳腺癌的新辅助化疗中,多西他赛及卡铂联合曲妥珠单抗疗效良好,且ER受体阴性患者可获较高的缓解率。

Clinical efficacy of neoadjuvant chemotherapy combined with trastuzumab for HER-2 positive breast cancer

Objective:To evaluate the clinical efficacy of neoadjuvant chemotherapy combined with trastuzumab for HER-2 positive breast cancer. Methods:Thirty-nine patients with HER-2 positive breast cancer were treated with six cycles of docetaxel plus carboplatin based neoadjuvant chemotherapy combined with trastuzumab,and then the overall clinical efficacy was observed and univariate analysis was performed between the estrogen receptor(ER) expression status of the cancer tissues and pathologic complete response(pCR) rate. Results:The overall response(OR) rate of the 39 patients was 94.9%(37/39).Of the patients,clinical complete response(cCR) was achieved in 26 cases,partial response(PR) in 11 cases,stable disease in 2 cases and no case of progressive disease(PD).The pCR was seen in 27 cases(69.2%).The univariate analysis showed that the pCR rate of the ER-negative and ER-positive patients was 82.4% and 59.1% respectively. Conclusion:The docetaxel plus carboplatin based neoadjuvant chemotherapy combined with trastuzumab has demonstrable efficacy for HER-2 positive breast cancer,and the ER-negative patients can obtain a higher response rate.